BAKER BROS. ADVISORS LP — BEONE MEDICINES LTD. ONC: Quarterly 13F Position History
BAKER BROS. ADVISORS LP has reported BEONE MEDICINES LTD. (ONC) on 41 13F-HR filings in Pactolio's tracked window, first appearing in Q1 2016. As of Q1 2026, the position is sized at 8,799,053 shares ($2.61B market value, 15.00% of the equity book).
- 8,799,053Shares Held (Latest Filing)
- $2.61BReported Market Value (Latest Filing)
- 15.00%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$60.2MQuarter-over-Quarter Value Change
- 13,301,597Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 41 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 8,799,053 | 0 | — | $2.61B | 15.00% | $296.97 |
| Q4 2025 | 8,799,053 | 0 | — | $2.67B | 15.65% | $303.81 |
| Q3 2025 | 8,799,053 | 0 | — | $3.00B | 21.66% | $340.70 |
| Q2 2025 | 8,799,053 | 0 | — | $2.13B | 20.66% | $242.07 |
| Q1 2025 | 8,799,053 | 732,827 | -7.7% | $2.39B | 26.50% | $272.17 |
| Q4 2024 | 9,531,880 | 1,037,017 | -9.8% | $1.76B | 18.81% | $184.71 |
| Q3 2024 | 10,568,897 | 0 | — | $2.37B | 24.59% | $224.51 |
| Q2 2024 | 10,568,897 | 0 | — | $1.51B | 19.27% | $142.67 |
| Q1 2024 | 10,568,897 | 0 | — | $1.65B | 20.73% | $156.39 |
| Q4 2023 | 10,568,897 | 1,100,000 | -9.4% | $1.91B | 21.69% | $180.36 |
| Q3 2023 | 11,668,897 | 0 | — | $2.10B | 12.10% | $179.87 |
| Q2 2023 | 11,668,897 | 0 | — | $2.08B | 12.04% | $178.30 |
| Q1 2023 | 11,668,897 | 0 | — | $2.51B | 13.68% | $215.53 |
| Q4 2022 | 11,668,897 | 0 | — | $2.57B | 15.41% | $219.94 |
| Q3 2022 | 11,668,897 | 0 | — | $1.57B | 10.30% | $134.82 |
| Q2 2022 | 11,668,897 | 0 | — | $1.89B | 10.71% | $161.85 |
| Q1 2022 | 11,668,897 | 0 | — | $2.20B | 12.65% | $188.60 |
| Q4 2021 | 11,668,897 | 0 | — | $3.16B | 15.38% | $270.93 |
| Q3 2021 | 11,668,897 | 0 | — | $4.24B | 18.60% | $363.00 |
| Q2 2021 | 11,668,897 | 0 | — | $4.00B | 17.59% | $343.19 |
| Q1 2021 | 11,668,897 | 0 | — | $4.06B | 17.61% | $348.08 |
| Q4 2020 | 11,668,897 | 1,632,700 | -12.3% | $3.02B | 11.36% | $258.39 |
| Q3 2020 | 13,301,597 | +1,524,312 | +12.9% | $3.81B | 15.22% | $286.44 |
| Q2 2020 | 11,777,285 | 0 | — | $2.22B | 9.79% | $188.40 |
| Q1 2020 | 11,777,285 | 0 | — | $1.45B | 8.93% | $123.11 |
| Q4 2019 | 11,777,285 | 0 | — | $1.95B | 10.38% | $165.76 |
| Q3 2019 | 11,777,285 | 0 | — | $1.44B | 9.81% | $122.46 |
| Q2 2019 | 11,777,285 | 182,539 | -1.5% | $1.46B | 9.92% | $123.95 |
| Q1 2019 | 11,959,824 | 0 | — | $1.58B | 10.11% | $132.00 |
| Q4 2018 | 11,959,824 | 0 | — | $1.68B | 13.74% | $140.26 |
| Q3 2018 | 11,959,824 | 0 | — | $2.06B | 13.57% | $172.22 |
| Q2 2018 | 11,959,824 | +6,130,395 | +105.2% | $1.84B | 13.81% | $153.73 |
| Q1 2018 | 5,829,429 | +1,980,198 | +51.4% | $979.3M | 8.30% | $168.00 |
| Q4 2017 | 3,849,231 | 49,200 | -1.3% | $376.1M | 3.26% | $97.72 |
| Q3 2017 | 3,898,431 | +225,256 | +6.1% | $403.3M | 3.27% | $103.46 |
| Q2 2017 | 3,673,175 | 0 | — | $165.3M | 1.45% | $45.00 |
| Q1 2017 | 3,673,175 | 0 | — | $134.5M | 1.10% | $36.61 |
| Q4 2016 | 3,673,175 | +1,760,495 | +92.0% | $111.5M | 1.09% | $30.36 |
| Q3 2016 | 1,912,680 | 0 | — | $58.9M | 0.53% | $30.81 |
| Q2 2016 | 1,912,680 | 0 | — | $57.0M | 0.60% | $29.80 |
| Q1 2016 | 1,912,680 | — | — | $56.1M | 0.59% | $29.31 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did BAKER BROS. ADVISORS LP first disclose a ONC position in 13F-HR filings?
BAKER BROS. ADVISORS LP first reported BEONE MEDICINES LTD. (ONC) on its 13F-HR filing for the period ending 2016-03-31 (Q1 2016). The position has appeared on 41 reported quarters within Pactolio's tracked window.
What was BAKER BROS. ADVISORS LP's most recent quarter-over-quarter share-count change in ONC?
BAKER BROS. ADVISORS LP held the same 8,799,053 shares of ONC between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent BAKER BROS. ADVISORS LP's cost basis in ONC?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.